Strecker E P, Gabelmann A, Boos I, Lucas C, Xu Z, Haberstroh J, Freudenberg N, Stricker H, Langer M, Betz E
Department of Radiology, Diakonissen-Hospital, Karlsruhe, Germany.
Cardiovasc Intervent Radiol. 1998 Nov-Dec;21(6):487-96. doi: 10.1007/s002709900309.
Polymer-coated, dexamethasone (DXM)-releasing stents were tested in order to assess the efficacy of DXM released locally for the prevention of stent restenosis due to intimal hyperplasia.
Strecker stents coated with a biodegradable membrane containing DXM were implanted percutaneously into the femoral artery in 14 dogs. The contralateral artery received a conventional non-coated stent serving as control. The drugs are eluted by degradation of the carrier membrane. Follow-up intraarterial digital subtraction angiography (DSA) was obtained at 3, 6, 9, 12, and 24 weeks with subsequent autopsy. Specimens for gross and microscopic pathology were obtained and histomorphometry was performed.
Four of 14 DXM-coated stents showed thrombotic occlusion within the first 3 weeks; ten DXM-coated stents remained patent. At follow-up DSA, DXM-coated stents showed a significantly wider lumen than the non-coated stents. At morphometry there was less intimal hyperplasia over DXM-coated stents than over non-coated stents (p < 0.05).
DXM-coated stents reduce neointimal hyperplasia in dogs when compared with non-coated stents.